Mechanisms of Action: Physiological Effects

Extracellular Proteases Increase Tolerance of *Bacillus subtilis* to Nafcillin. LINDA K. JOLLIFFE, RONALD J. DOYLE,* AND ULDIS N. STREIPS ........................................... 83–89

Selective Inhibition of Functional Lymphocyte Subpopulations by Ribavirin. CELESTE N. POWERS, DUANE L. PEAVY, AND VERNON KNIGHT* .......................................................... 108–114

In Vitro Susceptibility of *Streptococcus mutans* 6715 to Iodine and Sodium Fluoride, Singly and in Combination, at Various pH Values. PAGE W. CAUFIELD* AND YVONNE M. WANNEMUEHLER ................................................. 115–119

Effects of Sublethal Concentrations of Antimicrobial Agents on the Hemagglutination, Adhesion, and Ultrastructure of Pyelonephritogenic *Escherichia coli* Strains. VUOKKO VÄISÄNNEN, KARI LOUNATMAA, AND TIMO K. KOORHONEN* .......................................................... 120–127

Activities of Four Aminoglycosides at Subbactericidal Concentrations. LEONARD SCHRIRE,* ROY G. ROBINSON, RICHARD O. DOEHRING, AND HENDRIK J. KOORNHOF ..................... 137–139

Inhibition of Herpes Simplex Virus Replication by Methyl Daunosamine. JORDAN G. SPIVACK, WILLIAM H. PRUSOFF, AND THOMAS R. TRITTON* ..................................................... 176–179

Mechanisms of Resistance

Activity of Cefoperazone Against Ampicillin-Resistant Bacteria in Agar and Broth Dilution Tests. FRITZ H. KAYSER,* GIOVANNA MORENZONI, AND FRANÇOISE HOMBERGER ...................... 15–22

Herpes Simplex Virus Variants Resistant to High Concentrations of Acyclovir Exist in Clinical Isolates. DEBORAH S. PARRIS* AND JOYCE E. HARRINGTON ........................................ 71–77

Decreased Susceptibility to 4'-Deoxy-6'-N-Methylamikacin (BB-K311) Conferred by a Mutant Plasmid in *Escherichia coli*. MICHAEL H. PERLIN AND STEPHEN A. LERNER* .................. 78–82

Penicillin-Resistant and Penicillin-Tolerant Mutants of Group A Streptococci. LAURENT GUTMANN AND ALEXANDER TOMASZ* 128–136

Transfer of IncN Plasmids to *Pseudomonas aeruginosa*. GINETTE TARDIF AND ROBERT B. GRANT* ........................................ 142–144

Penicillin-Binding Proteins in a *Staphylococcus aureus* Strain Resistant to Specific β-Lactam Antibiotics. NAJSIKA H. GEORGOPAPADAKOU,* SANDRA A. SMITH, AND DANIEL P. BONNER ......................................................... 172–175

Susceptibility

In Vitro Activity of Norfloxacin, a Quinoline-Carboxylic Acid, Compared with That of β-Lactams, Aminoglycosides, andTrimethoprim. HAROLD C. NEU* AND PORNPEN LABTHAVIKUL 23–27

Quality Control and Interpretive Criteria for the Azlocillin Disk Diffusion Susceptibility Test. ROBERT J. FASS .................. 28–31

Continued on following page
In Vitro Activity of Trimethoprim and Sulfamethoxazole Against *Listeria monocytogenes*. DEAN L. WINSLOW* and GEORGE A. PANKEY ................................. 51–54


In Vitro Activity of Antibiotics Commonly Used in the Treatment of *Streptococcus pneumoniae* Isolates with Different Susceptibilities to Penicillin. MARTHA M. TARPAY,* DAVID F. WELCH, HAMID SALARI, AND MELVIN I. MARKS.... 145–147

In Vitro Synergistic Activity of Ethambutol, Isoniazid, Kanamycin, Rifampin, and Streptomycin Against *Mycobacterium avium-intracellulare* Complex. BARBARA L. ZIMMER, DONALD R. DEYOUNG, AND GLENN D. ROBERTS* ............................ 148–150

Aminoglycoside-Resistant Gram-Negative Bacilli in a Community Hospital: Comparative In Vitro Activity of Cefotaxime, Moxalactam, Cefoperazone, and Piperacillin. C. RICHARD MAGNUSSEN,* MARIA T. SAMMARTINO, AND KAREN D. ERNEST 154–156

In Vitro Activity of Temocillin (BRL 17421), a Novel Beta-Lactamase-Stable Penicillin. LUDO VERBIST .................................................. 157–161

In Vitro Activity of the Two Principal Oxidative Metabolites of Metronidazole Against *Bacteroides fragilis* and Related Species. I. HALLER .......................................................... 165–166

Comparative In Vitro Activities of Azlocillin-Cefotaxime and Azlocillin-Tobramycin Combinations Against Blood and Multidrug-Resistant Bacterial Isolates. ROBERT J. FASS ................. 167–169

Analytical Procedures

Evaluation of the Titertek Multiskan for Determining Minimal Inhibitory Concentration Endpoints. VALERIO M. GENTA,* LAURENCE R. MCCARTHY, MELANIE HERRICK, AND FRED ROSE 151–153


Clinical Therapeutics

Ceftriaxone: In Vitro Studies and Clinical Evaluation. JOHN W. GNANN, JR.,* WILLIAM E. GOETTER, ANN M. ELLIOTT, AND C. GLENN COBBS .......................... 1–9

Clinical Evaluation of the Therapeutic Efficacy and Tolerability of Piperacillin. BROBSON LUTZ,* WILLIAM MOGABGB, BARBARA HOLMES, BEE POLLOCK, AND ROSE BEVILLE ........... 10–14

Continued on following page
Randomized Comparative Study of Moxalactam and Cefazolin in the Treatment of Acute Urinary Tract Infections in Adults. A. SCOTT LEA, ARTHUR W. SUDAN, BRUCE A. WOOD, AND LAYNE O. GENTRY* ............................................. 32–35

Ceftriaxone (Ro 13-9904) Therapy of Serious Infection. ROBERT W. BRADSHER .................................................. 36–42

Efficacy of a Twelve-Hourly Ceftriaxone Regimen in the Treatment of Serious Bacterial Infections. MELANIE J. MASLOW,* JE- ROME F. LEVINE, ALAN A. POLLOCK, MICHAEL S. SIMBERKOFF, AND JAMES J. RAHAL, JR. ................................. 103–107

Pharmacology

Pharmacokinetics of Ketoconazole in Patients with Neoplastic Diseases. ANDREW W. MAKSYMUK, HILLEL B. LEVINE, AND GERALD P. BODEY* ...................................................... 43–46

Moxalactam Pharmacokinetics in Children. MARIO F. ROMAGNOLI, KERRIE FLYNN, GEORGE R. SIBER, AND DONALD A. GOLDMANN* .......................................................... 47–50

Metabolism of Thienamycin and Related Carbapenem Antibiotics by the Renal Dipeptidase, Dehydropeptidase-I. HELMUT KROPP,* JON G. SUNDELOF, RICHARD HAJDU, AND FREDERICK M. KAHAN ........................................... 62–70

Single- and Multiple-Dose Pharmacokinetics of Moxalactam in Normal Subjects. KAREN S. ISRAEL,* HENRY R. BLACK, GORDON L. BRIER, JAMES D. WOLNY, AND KARL A. DESANTE ......... 94–102

Comparative Biliary Excretion of Cephalosporins in Normal and Partially Hepatectomized Rats. NICOLA L. M. HUMPHRIES, D. GORDON TASKER,* AND STEPHEN J. KARRAN ............... 170–171

Errata

Vancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects. ROBERT A. BLOUIN, LARRY A. BAUER, DELWYN D. MILLER, KENNETH E. RECORD, AND WARD O. GRIFFEN, JR. 180

Antibiotic Entry into Human Polymorphonuclear Leukocytes. RICHARD C. PROKESCH AND W. LEE HAND ............. 180

* Asterisk refers to person to whom inquiries regarding the paper should be addressed.